about
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)A review of the treatment of chronic hepatitis C virus infection in cirrhosis.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.HBV and HCV therapy.Treatment of patients with HCV related cirrhosis: many rewards with very few risks.Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside.New horizons in hepatitis C antiviral therapy with direct-acting antivirals.PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Hepatitis C treatment in patients with kidney disease.De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).Hepatorenal syndrome and novel advances in its management.Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.Hepatitis C genotype 3: a tough match for interferon-free regimens.Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis.Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis.The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
P50
Q26865724-73FA9479-0C1A-4BDD-B218-0AF02ED470EEQ33394104-46DCFFA5-161B-49C4-8A03-AED011F7F0A5Q34626479-0B132BCA-D43B-43F2-AB7A-DBB4ABC8FF1CQ35259824-E4449594-07D2-40CF-B45E-46832EEFE0F8Q36142732-7D93214F-BBEC-4C32-A6FD-B515672E1101Q36699256-5A502D98-7A66-428B-A973-BA04252BE6E1Q37608271-85F194C1-E45B-4418-A996-D5FF611F72E7Q37774238-742E8A38-3B51-4BB4-8E9A-B1FB63FCCFFAQ37857522-7141D2F1-3AA7-44E0-92D7-E10B4B236B5DQ37970447-4A3EC815-1900-4F72-9192-E0A2AAB0F55AQ38018476-A0089A50-D5AE-4D51-9851-431D289B6F99Q38023098-E9524516-5304-4448-884B-2D99E1510EC2Q38046452-AEAB26E8-5300-48A2-AF0E-919724CCD599Q38087250-393758B3-4ACB-428A-969B-E1105A568DA1Q38102776-E52764BA-CA95-463F-A1EE-6161D8E8BCACQ38119104-592D7767-CBEB-48D8-832F-269C9395E0DAQ38169598-9B28C4F6-86A8-49EC-B7CD-3EABCE592380Q38172808-2E718D33-E12C-4962-8EAE-9C3DF1C35D35Q38189959-9E021B33-6F4B-46F1-AC56-76AFA698E921Q39526702-FCDA2614-E1A2-42D4-BC6A-730ACACF6EBDQ40155391-FD9FA2AB-FC48-45E4-9DAC-1A948AEEDF69Q40753034-FED92C71-ECA8-4AFE-8896-8EEF2D72D874Q42223386-62739A11-C0D8-4553-9943-5377F4D33D79Q42232936-404631C5-CED2-42B5-90C0-07596F937DFCQ42235440-389DC367-CE3E-4D13-AD30-C1005CFA67EAQ42245714-34722C55-4AE6-4FAB-B39D-39E5F1F7EB2DQ42270709-72A9674D-91A4-4D02-ABDD-695DFEE91F21Q42977090-7A7C7264-E0EA-43DB-AE6B-F1C237DA9EACQ42980606-D9EFB8F6-A3FF-4872-BE1B-07DBC01CE4B5Q42982540-48B11464-8BEF-4041-8E11-97B031B2BA2FQ42984817-913280D4-F3E7-45FF-B84A-A8F469557477Q42987674-C5B81FAD-07BB-4CDA-916D-E58E60188AA2Q42991111-618D6146-F7AA-4F40-A642-013689B024FBQ42991226-4431D436-A9F9-41E4-8BBE-1EBBF30CE93DQ42991475-DA806552-D30C-4C74-8750-964E5EDB12B4Q42992721-1CA745A5-6663-4C13-B028-34EE0EF9D707Q42998773-BA8A82C4-C0DB-45FA-B7DD-839BF6627E04Q42999597-29E6404C-E63D-416B-B4E3-82DCD46B148FQ43038606-2425FE17-E078-4AEB-8B1C-3296797E9F63Q43039467-1D8776C0-6BEE-4F3F-BBB0-FFD904D0E601
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessio Aghemo
@ast
Alessio Aghemo
@en
Alessio Aghemo
@es
Alessio Aghemo
@nl
type
label
Alessio Aghemo
@ast
Alessio Aghemo
@en
Alessio Aghemo
@es
Alessio Aghemo
@nl
altLabel
Aghemo A
@en
prefLabel
Alessio Aghemo
@ast
Alessio Aghemo
@en
Alessio Aghemo
@es
Alessio Aghemo
@nl
P106
P1153
12779561100
P21
P31
P4012
P496
0000-0003-0941-3226